Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone

被引:155
作者
Clines, GA [1 ]
Guise, TA [1 ]
机构
[1] Univ Virginia, Dept Med, Div Endocrinol & Metab, Charlottesville, VA 22908 USA
关键词
D O I
10.1677/erc.1.00543
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Calcium homeostasis is a tightly regulated process involving the co-ordinated efforts of the skeleton, kidney, parathyroid glands and intestine. Neoplasms can alter this homeostasis indirectly through the production of endocrine factors resulting in humoral hypercalcaemia of malignancy. Relatively common with breast and lung cancer, this paraneoplastic condition is most often due to tumour production of parathyroid hormone-related protein and ensuing increased osteoclastic bone resorption. Although control of hypercalcaemia is generally successful, the development of this complication is associated with a poor prognosis. The metastasis of tumour cells to bone represents another skeletal complication of malignancy. As explained in the 'seed and soil' hypothesis, bone represents a fertile ground for cancer cells to flourish. The molecular mechanisms of this mutually beneficial relationship between bone and cancer cells are beginning to be understood. In the case of osteolytic bone disease, tumour-produced parathyroid hormone-related protein stimulates osteoclasts that in turn secrete tumour-activating transforming growth factor-P that further stimulates local cancer cells. This 'vicious cycle' of bone metastases represents reciprocal bone/cancer cellular signals that likely modulate osteoblastic bone metastatic lesions as well. The development of targeted therapies to either block initial cancer cell chemotaxis, invasion and adhesion or to break the 'vicious cycle' is dependent on a more complete understanding of bone metastases. Although bisphosphonates delay progression of skeletal metastases, it is clear that more effective therapies are needed. Cancer-associated bone morbidity remains a major public health problem, and to improve therapy and prevention it is important to understand the pathophysiology of the effects of cancer on bone. This review will detail scientific advances regarding this area.
引用
收藏
页码:549 / 583
页数:35
相关论文
共 334 条
[31]  
BOYDE A, 1986, Scanning Electron Microscopy, P1537
[32]   Regulation of 25-hydroxyvitamin D3 1α-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3 [J].
Brenza, HL ;
DeLuca, HF .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 381 (01) :143-152
[33]   HYPERCALCEMIA ASSOCIATED WITH INCREASED SERUM CALCITRIOL LEVELS IN 3 PATIENTS WITH LYMPHOMA [J].
BRESLAU, NA ;
MCGUIRE, JL ;
ZERWEKH, JE ;
FRENKEL, EP ;
PAK, CYC .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (01) :1-7
[34]   CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID [J].
BROWN, EM ;
GAMBA, G ;
RICCARDI, D ;
LOMBARDI, M ;
BUTTERS, R ;
KIFOR, O ;
SUN, A ;
HEDIGER, MA ;
LYTTON, J ;
HEBERT, SC .
NATURE, 1993, 366 (6455) :575-580
[35]   Calcium stimulates parathyroid hormone-related protein production in Leydig tumor cells through a putative cation-sensing mechanism [J].
Buchs, N ;
Manen, D ;
Bonjour, JP ;
Rizzoli, R .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (05) :500-505
[36]   PARATHYROID-HORMONE RELATED PROTEIN AND SKELETAL MORBIDITY IN BREAST-CANCER [J].
BUNDRED, NJ ;
WALKER, RA ;
RATCLIFFE, WA ;
WARWICK, J ;
MORRISON, JM ;
RATCLIFFE, JG .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :690-692
[37]   PARATHYROID-HORMONE RELATED PROTEIN AND HYPERCALCEMIA IN BREAST-CANCER [J].
BUNDRED, NJ ;
RATCLIFFE, WA ;
WALKER, RA ;
COLEY, S ;
MORRISON, JM ;
RATCLIFFE, JG .
BRITISH MEDICAL JOURNAL, 1991, 303 (6816) :1506-1509
[38]   IMMUNOCHEMICAL CHARACTERIZATION OF CIRCULATING PARATHYROID-HORMONE RELATED PROTEIN IN PATIENTS WITH HUMORAL HYPERCALCEMIA OF CANCER [J].
BURTIS, WJ ;
BRADY, TG ;
ORLOFF, JJ ;
ERSBAK, JB ;
WARRELL, RP ;
OLSON, BR ;
WU, TL ;
MITNICK, ME ;
BROADUS, AE ;
STEWART, AF .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (16) :1106-1112
[39]   Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate [J].
Buzdar, A ;
Douma, J ;
Davidson, N ;
Elledge, R ;
Morgan, M ;
Smith, R ;
Porter, L ;
Nabholtz, J ;
Xiang, X ;
Brady, C .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3357-3366
[40]   Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial [J].
Carducci, MA ;
Padley, RJ ;
Breul, J ;
Vogelzang, NJ ;
Zonnenberg, BA ;
Daliani, DD ;
Schulman, CC ;
Nabulsi, AA ;
Humerickhouse, RA ;
Weinberg, MA ;
Schmitt, JL ;
Nelson, JB .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :679-689